Pfizer says its vaccine booster restores full protection against COVID-19
CBSN
Pfizer and BioNTech said Thursday that a late-stage trial of the drugmakers' COVID-19 vaccine booster showed it restored full protection against the disease. In a test involving 10,000 participants, the additional shot was 95.6% effective against the disease, according to the companies.
Pfizer and BioNTech said they plan to submit the data to the Food and Drug Administration and other regulatory agencies to support the license of boosters in the U.S. and other nations. Last month, the Centers for Disease Control and Prevention endorsed Pfizer's booster shots for several groups of people, including seniors over 65 years old, nursing home residents and adults at least 50 years old with "underlying medical conditions."
The companies said the trial involved people who were 16 and older, and represents the first efficacy results from any randomized, controlled COVID-19 vaccine booster test. The results demonstrate the benefits of booster shots to fight the disease, Pfizer CEO Albert Bourla said. in a statement.

The Trump administration deployed ICE and other Homeland Security agents to 14 of the nation's airports on Monday to help shuttle passengers through overcrowded TSA checkpoints. In one airport, the security line wait-time was up to six hours. Nicole Sganga and Kaia Hubbard contributed to this report. In:












